493 related articles for article (PubMed ID: 11589485)
1. An observational study on the epidemiology of respiratory tract bacterial pathogens and their susceptibility to four injectable beta-lactam antibiotics: piperacillin, piperacillin/tazobactam, ceftazidime and ceftriaxone.
Varotto F; Maria GD; Azzaro R; Bellissima P; Amato R; Fogliani V; Muscianisi G; Vitale S; Girbino G; Andò F; Laganà P; Delia S; Jacoviello C; Maierna G; Pezza A; Covelli I; Magrì M; Napoletano G; Rossi A; Marone P; Sanguinetti C; Pela R; Tedeschi D; Viola B; Cicciarella S; Messina G; Rizza S; Fraschini F
J Chemother; 2001 Aug; 13(4):413-23. PubMed ID: 11589485
[TBL] [Abstract][Full Text] [Related]
2. Susceptibility survey of piperacillin/tazobactam and some beta-lactam comparators in Italy.
Stefani S; Bonfiglio G; Bianchi C; Zollo A; Nicoletti G
Drugs Exp Clin Res; 1998; 24(2):105-13. PubMed ID: 9675551
[TBL] [Abstract][Full Text] [Related]
3. Comparisons of parenteral broad-spectrum cephalosporins tested against bacterial isolates from pediatric patients: report from the SENTRY Antimicrobial Surveillance Program (1998-2004).
Jones RN; Sader HS; Fritsche TR; Pottumarthy S
Diagn Microbiol Infect Dis; 2007 Jan; 57(1):109-16. PubMed ID: 16930923
[TBL] [Abstract][Full Text] [Related]
4. Potency and antimicrobial spectrum update for piperacillin/tazobactam (2000): emphasis on its activity against resistant organism populations and generally untested species causing community-acquired respiratory tract infections.
Johnson DM; Biedenbach DJ; Jones RN
Diagn Microbiol Infect Dis; 2002 May; 43(1):49-60. PubMed ID: 12052629
[TBL] [Abstract][Full Text] [Related]
5. In vitro antimicrobial activity of piperacillin/tazobactam in comparison with other broad-spectrum beta-lactams.
Roland RK; Mendes RE; Silbert S; Bolsoni AP; Sader HS
Braz J Infect Dis; 2000 Oct; 4(5):226-35. PubMed ID: 11063554
[TBL] [Abstract][Full Text] [Related]
6. Argentinean collaborative multicenter study on the in vitro comparative activity of piperacillin-tazobactam against selected bacterial isolates recovered from hospitalized patients.
Casellas JM; Tomé G; Bantar C; Bertolini P; Blázquez N; Borda N; Couto E; Cudmani N; Guerrera J; Juárez MJ; López T; Littvik A; Méndez E; Notario R; Ponce G; Quinteros M; Salamone F; Sparo M; Sutich E; Vaylet S; Wolff L
Diagn Microbiol Infect Dis; 2003 Nov; 47(3):527-37. PubMed ID: 14596972
[TBL] [Abstract][Full Text] [Related]
7. Bactericidal activity of ertapenem against major intra-abdominal pathogens.
Borbone S; Cascone C; Santagati M; Mezzatesta ML; Stefani S
Int J Antimicrob Agents; 2006 Nov; 28(5):396-401. PubMed ID: 17045463
[TBL] [Abstract][Full Text] [Related]
8. In vitro activity of piperacillin/tazobactam versus other broad-spectrum antibiotics against nosocomial gram-negative pathogens isolated from burn patients.
Mokaddas E; Rotimi VO; Sanyal SC
J Chemother; 1998 Jun; 10(3):208-14. PubMed ID: 9669645
[TBL] [Abstract][Full Text] [Related]
9. Cross-susceptibility of cefpirome and four other beta-lactams against isolates from haematology/oncology and intensive care units. International Study Group.
Spencer RC
Scand J Infect Dis Suppl; 1993; 91():25-32. PubMed ID: 8290900
[TBL] [Abstract][Full Text] [Related]
10. Ceftolozane/tazobactam activity tested against aerobic Gram-negative organisms isolated from intra-abdominal and urinary tract infections in European and United States hospitals (2012).
Sader HS; Farrell DJ; Flamm RK; Jones RN
J Infect; 2014 Sep; 69(3):266-77. PubMed ID: 24780763
[TBL] [Abstract][Full Text] [Related]
11. Drug resistance patterns of bacteria isolated from patients with nosocomial pneumonia at Tehran hospitals during 2009-2011.
Haeili M; Ghodousi A; Nomanpour B; Omrani M; Feizabadi MM
J Infect Dev Ctries; 2013 Apr; 7(4):312-7. PubMed ID: 23592640
[TBL] [Abstract][Full Text] [Related]
12. Comparative in vitro evaluation of piperacillin/tazobactam in a tertiary care hospital.
Platsouka E; Zissis NP; Constantoulaki S; Paniara O
J Chemother; 1997 Oct; 9(5):336-40. PubMed ID: 9373788
[TBL] [Abstract][Full Text] [Related]
13. Comparative antimicrobial susceptibility of aerobic and facultative bacteria from community-acquired bacteremia to ertapenem in Taiwan.
Lee SC; Huang SS; Lee CW; Fung CP; Lee N; Shieh WB; Siu LK
BMC Infect Dis; 2007 Jul; 7():79. PubMed ID: 17640342
[TBL] [Abstract][Full Text] [Related]
14. Epidemiology and antimicrobial susceptibility profiles of Gram-negative bacteria causing urinary tract infections in the Asia-Pacific region: 2009-2010 results from the Study for Monitoring Antimicrobial Resistance Trends (SMART).
Lu PL; Liu YC; Toh HS; Lee YL; Liu YM; Ho CM; Huang CC; Liu CE; Ko WC; Wang JH; Tang HJ; Yu KW; Chen YS; Chuang YC; Xu Y; Ni Y; Chen YH; Hsueh PR
Int J Antimicrob Agents; 2012 Jun; 40 Suppl():S37-43. PubMed ID: 22749057
[TBL] [Abstract][Full Text] [Related]
15. Antimicrobial susceptibility pattern of bacteria isolated from patients with urinary tract infection.
Khan IU; Mirza IA; Ikram A; Afzal A; Ali S; Hussain A; Fayyaz M; Ghafoor T
J Coll Physicians Surg Pak; 2014 Nov; 24(11):840-4. PubMed ID: 25404444
[TBL] [Abstract][Full Text] [Related]
16. In-vitro activity of piperacillin and tazobactam combination against clinically significant bacteria.
Obi CL; Makandiramba B; Robertson V; Tswana SA; Moyo SR; Nziramasanga P
East Afr Med J; 1998 Mar; 75(3):162-5. PubMed ID: 9640815
[TBL] [Abstract][Full Text] [Related]
17. Multicenter evaluation of the in vitro activity of piperacillin-tazobactam compared with eleven selected beta-lactam antibiotics and ciprofloxacin against more than 42,000 aerobic gram-positive and gram-negative bacteria. In Vitro Susceptibility Surveillance Group.
Murray PR; Cantrell HF; Lankford RB
Diagn Microbiol Infect Dis; 1994 Jun; 19(2):111-20. PubMed ID: 7805355
[TBL] [Abstract][Full Text] [Related]
18. Comparative in vitro activity of Meropenem, Imipenem and Piperacillin/tazobactam against 1071 clinical isolates using 2 different methods: a French multicentre study.
Joly-Guillou ML; Kempf M; Cavallo JD; Chomarat M; Dubreuil L; Maugein J; Muller-Serieys C; Roussel-Delvallez M
BMC Infect Dis; 2010 Mar; 10():72. PubMed ID: 20298555
[TBL] [Abstract][Full Text] [Related]
19. Antipseudomonal activity of piperacillin/tazobactam: more than a decade of experience from the SENTRY Antimicrobial Surveillance Program (1997-2007).
Jones RN; Stilwell MG; Rhomberg PR; Sader HS
Diagn Microbiol Infect Dis; 2009 Nov; 65(3):331-4. PubMed ID: 19822273
[TBL] [Abstract][Full Text] [Related]
20. New species-related MIC breakpoints for early detection of development of resistance among gram-negative bacteria in Swedish intensive care units.
Hanberger H; Nilsson LE; Claesson B; Kärnell A; Larsson P; Rylander M; Svensson E; Sörberg M; Sörén L
J Antimicrob Chemother; 1999 Nov; 44(5):611-9. PubMed ID: 10552977
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
